We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
Unlock the market timeline & signal feed
32 signals in the last 90 days.
The order this company entered each market — oldest to newest
12 active postings
Key Account Manager Neuro Science / Rare Disease
Sign up to see the full signal feed
How Ipsen's international expansion compares to its competitors
IpsenYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 IpsenYou | 12 | 0 | 0% | 28 | 21 |
Director, New Products Strategy and Innovation
View postingCambridge, MA · last wk.
Microbiologist – Ipsen Wrexham
View postingWrexham, Wales, United Kingdom · 2w ago
National Corporate Accounts Director
View postingNew York, NY · last wk.
Glasses on. Meetings moved outside. Coffee on the terrasse. This is what spring at Ipsen HQ looks like. ☀️Same mission. Much better backdrop. ...
EndedParis 🇫🇷 London 🇬🇧 Cambridge 🇺🇸Different views outside the windows, but the same spirit inside: we share ideas, move fast, and focus on what matters most—people and patients.Same mission. Just a few time zones apart. ...
Ended
Download the 2025 Integrated Annual Report
EndedIpsen, a global biopharmaceutical company, has announced changes to its Executive Committee. The announcement was made in Paris, France.
Ipsen reports 11.6% sales growth at CER in Q1 2025, driven by all three therapeutic areas. The company confirms its full-year 2025 financial guidance and highlights pipeline progress.
Ipsen reports positive phase III results for Onivyde in pancreatic cancer, showing 19.5 months median overall survival in long-term survivors with metastatic pancreatic adenocarcinoma.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Ipsen's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
